BACKGROUND: Fibrocytes are integral in the development of fibroproliferative disease. The CXCL12/CXCR4 chemokine axis has been shown to play a central role in fibrocyte migration and the development of bronchiolitis obliterans (BO) after lung transplantation. Inhibition of the mammalian target of rapamycin (mTOR) pathway with rapamycin has been shown to decrease expression of both CXCR4 and its receptor agonist CXCL12. Thus, we hypothesized that rapamycin treatment would decrease fibrocyte trafficking into tracheal allografts and prevent BO. METHODS: A total alloantigenic mismatch murine heterotopic tracheal transplant (HTT) model of BO was used. Animals were either treated with rapamycin or dimethyl sulfoxide (DMSO) for 14 days after tracheal transplantation. Fibrocyte levels were assessed by flow cytometry, and allograft neutrophil, CD3(+) T-cell, macrophage, and smooth muscle actin (SMA) levels were assessed by immunohistochemistry. Tracheal luminal obliteration was assessed on hematoxylin and eosin (H&E) stains. RESULTS: Compared with DMSO-treated controls, rapamycin-treated mice showed a significant decrease in fibrocyte levels in tracheal allografts. Fibrocyte levels in recipient blood showed a similar pattern, although it was not statistically significant. Furthermore, animals treated with rapamycin showed a significant decrease in tracheal allograft luminal obliteration compared with controls. Based on immunohistochemical analyses, populations of α-SMA-positive (α-SMA(+)) cells, neutrophils, CD3(+) T cells, and macrophages were all decreased in rapamycin-treated allografts versus DMSO controls. CONCLUSIONS: Rapamycin effectively reduces recruitment of fibrocytes into tracheal allografts and mitigates development of tracheal luminal fibrosis. Further studies are needed to determine the cellular and molecular mechanisms that mediate the protective effect of rapamycin against BO.
BACKGROUND: Fibrocytes are integral in the development of fibroproliferative disease. The CXCL12/CXCR4 chemokine axis has been shown to play a central role in fibrocyte migration and the development of bronchiolitis obliterans (BO) after lung transplantation. Inhibition of the mammalian target of rapamycin (mTOR) pathway with rapamycin has been shown to decrease expression of both CXCR4 and its receptor agonist CXCL12. Thus, we hypothesized that rapamycin treatment would decrease fibrocyte trafficking into tracheal allografts and prevent BO. METHODS: A total alloantigenic mismatch murine heterotopic tracheal transplant (HTT) model of BO was used. Animals were either treated with rapamycin or dimethyl sulfoxide (DMSO) for 14 days after tracheal transplantation. Fibrocyte levels were assessed by flow cytometry, and allograft neutrophil, CD3(+) T-cell, macrophage, and smooth muscle actin (SMA) levels were assessed by immunohistochemistry. Tracheal luminal obliteration was assessed on hematoxylin and eosin (H&E) stains. RESULTS: Compared with DMSO-treated controls, rapamycin-treated mice showed a significant decrease in fibrocyte levels in tracheal allografts. Fibrocyte levels in recipient blood showed a similar pattern, although it was not statistically significant. Furthermore, animals treated with rapamycin showed a significant decrease in tracheal allograft luminal obliteration compared with controls. Based on immunohistochemical analyses, populations of α-SMA-positive (α-SMA(+)) cells, neutrophils, CD3(+) T cells, and macrophages were all decreased in rapamycin-treated allografts versus DMSO controls. CONCLUSIONS:Rapamycin effectively reduces recruitment of fibrocytes into tracheal allografts and mitigates development of tracheal luminal fibrosis. Further studies are needed to determine the cellular and molecular mechanisms that mediate the protective effect of rapamycin against BO.
Authors: G I Snell; V G Valentine; P Vitulo; A R Glanville; D C McGiffin; J E Loyd; A Roman; R Aris; A Sole; A Hmissi; U Pirron Journal: Am J Transplant Date: 2006-01 Impact factor: 8.086
Authors: John M Kovarik; Gregory I Snell; Vincent Valentine; Robert Aris; Charles K N Chan; Heinz Schmidli; Ulrich Pirron Journal: J Heart Lung Transplant Date: 2006-04 Impact factor: 10.247
Authors: J A Belperio; M P Keane; M D Burdick; J P Lynch; Y Y Xue; A Berlin; D J Ross; S L Kunkel; I F Charo; R M Strieter Journal: J Clin Invest Date: 2001-08 Impact factor: 14.808
Authors: Phuong-Thu T Pham; Phuong-Chi T Pham; Gabriel M Danovitch; David J Ross; H Albin Gritsch; Elizabeth A Kendrick; Jennifer Singer; Tariq Shah; Alan H Wilkinson Journal: Transplantation Date: 2004-04-27 Impact factor: 4.939
Authors: Jan Groetzner; Felix Kur; Fritz Spelsberg; Jurgen Behr; Lorenz Frey; Iris Bittmann; Michael Vogeser; Peter Ueberfuhr; Bruno Meiser; Rudolf Hatz; Bruno Reichart Journal: J Heart Lung Transplant Date: 2004-05 Impact factor: 10.247
Authors: Roderick J Phillips; Marie D Burdick; Kurt Hong; Marin A Lutz; Lynne A Murray; Ying Ying Xue; John A Belperio; Michael P Keane; Robert M Strieter Journal: J Clin Invest Date: 2004-08 Impact factor: 14.808
Authors: Melissa B King-Biggs; Jordan M Dunitz; Soon J Park; S Kay Savik; Marshall I Hertz Journal: Transplantation Date: 2003-05-15 Impact factor: 4.939
Authors: Yunge Zhao; Jacob R Gillen; Akshaya K Meher; Jordan A Burns; Irving L Kron; Christine L Lau Journal: J Thorac Cardiovasc Surg Date: 2015-09-07 Impact factor: 5.209
Authors: Takeshi Mimura; Natalie Walker; Yoshiro Aoki; Casey M Manning; Benjamin J Murdock; Jeffery L Myers; Amir Lagstein; John J Osterholzer; Vibha N Lama Journal: Am J Pathol Date: 2015-04-04 Impact factor: 4.307
Authors: Jacob R Gillen; Yunge Zhao; David A Harris; Damien J LaPar; Irving L Kron; Christine L Lau Journal: Ann Thorac Surg Date: 2013-06-24 Impact factor: 4.330